Nicotine therapeutic benefits: Difference between revisions
| Line 303: | Line 303: | ||
='''Behcet's disease'''= | ='''Behcet's disease'''= | ||
*See also: Aphthous ulcers | |||
===2010 [https://academic.oup.com/rheumatology/article/49/3/501/1786816 Nicotine-patch therapy on mucocutaneous lesions of Behçet’s disease: a case series]=== | ===2010 [https://academic.oup.com/rheumatology/article/49/3/501/1786816 Nicotine-patch therapy on mucocutaneous lesions of Behçet’s disease: a case series]=== | ||
*In this report, we describe five ex-smoker [[Special:MyLanguage/Abbreviations|'''BD''']] patients with active mucocutaneous lesions, not responsive to standard pharmacological treatments and treated with transdermal nicotine patches. Four out of five patients quickly responded to nicotine-patch therapy and experienced a complete regression of all mucocutaneous lesions within 6 months of observation. | *In this report, we describe five ex-smoker [[Special:MyLanguage/Abbreviations|'''BD''']] patients with active mucocutaneous lesions, not responsive to standard pharmacological treatments and treated with transdermal nicotine patches. Four out of five patients quickly responded to nicotine-patch therapy and experienced a complete regression of all mucocutaneous lesions within 6 months of observation. | ||